A critical analysis of serogroup B meningococcal disease burden in Brazil (2001–2015): implications for public health decisions

References

• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20. doi:10.1007/978-1-61779-346-2_1.
   PubMedGoogle Scholar
• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196–1210. doi:10.1016/S0140-6736(07)61016-2.
   PubMed Web of Science ®Google Scholar
• Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19(4):566–73. doi:10.3201/eid1904.111799.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Meningococcal infections. In: Kimberlin DW, Brady M, Jackson MA, Long SS, editors. Red book: report of the 2018 committee on infectious diseases. 31th ed. Elk Grove Village (IL): American Academy of Pediatrics; 2018. p. 550–61.
   Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. New Engl J of Med. 2001;344(18):1378–88. doi:10.1056/NEJM200105033441807.
   PubMed Web of Science ®Google Scholar
• Presa JV, de Almeida RS, Spinardi JR, Cane A. Epidemiological burden of meningococcal disease in Brazil: a systematic literature review and data base analysis. Int J InfectDis. 2019;80:137–46. doi:10.1016/j.ijid.2019.05.006.
   PubMed Web of Science ®Google Scholar
• de Moraes JC, Barata RB. Meningococcal disease in São Paulo, Brazil, in the 20th century: epidemiological characteristics. Cad Saúde Pública. 2005;21(5):1458–71. doi:10.1590/S0102-311X2005000500019.
   PubMedGoogle Scholar
• Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Sáfadi MAP. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(2):B26–36. doi:10.1016/j.vaccine.2011.12.032.
   PubMedGoogle Scholar
• Villena R, Safadi MAP, Valenzuela MT, Torres JP, Finn A, O´Ryan M. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. Hum Vaccin Immunother. 2018;14(5):1042–57. doi:10.1080/21645515.2018.1458175.
   PubMed Web of Science ®Google Scholar
• Brazil. Ministry of Health. List of infectious diseases considered of mandatory notification. [accessed 2019 Aug 13]. http://bvsms.saude.gov.br/bvs/saudelegis/gm/2016/prt0204_17_02_2016.html
   Google Scholar
• Brazil. Ministry of Health. Health surveillance guide; Brasília (DF), 2017 [accessed 2019 Jun 31]. http://portalarquivos.saude.gov.br/images/pdf/2017/outubro/06/Volume-Unico-2017.pdf
   Google Scholar
• Sridhar S, Greenwood B, Head C, Plotkin SA, Sáfadi MA, Saha S, Taha M-K, Tomori O, Gessner B. Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infect Dis. 2015;15(11):1334–46. doi:10.1016/S1473-3099(15)00217-0.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control ECDC. Invasive meningococcal disease – annual epidemiological report for 2016. ECDC; 2016. [accessed 2019 May 20]. https://ecdc.europa.eu/sites/portal/files/documents/AER_for_2016-invasive-meningococcal-disease_1.pdf.
   Google Scholar
• Centre of Disease Control. CDC. enhanced meningococcal disease surveillance report, 2017. [accessed 2019 May 20]. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2017.pdf
   Google Scholar
• Safadi MA, O’Ryan M, Valenzuela MT, Brandileone MC, Gorla MC, de Lemos AP, Moreno G, Vazquez JA, López EL, Taha M-K, et al. The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations. Vaccine. 2015;33(48):6529–36. doi:10.1016/j.vaccine.2015.10.055.
   PubMed Web of Science ®Google Scholar
• US centers for disease control and prevention. Active Bacterial Core surveillance (ABCs). [accessed 2019 Jun 20] https://www.cdc.gov/abcs/overview/background.html
   Google Scholar
• Australian Government, Department of Health. Meningococcal–Australian meningococcal surveillance programme annual reports. [accessed 2019 Jun 20]. https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-annlrpt-menganrep.htm
   Google Scholar
• Sáfadi MAP, de Los Monteros LEE, López EL, Sàez-Llorens X, Lemos AP, Moreno-Espinosa S, Ayala SG, Torres JP, de Moraes JC, Vázquez JA, et al. The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the global meningococcal initiative. Expert Rev Vaccines. 2013;12:903–15. doi:10.1586/14760584.2013.814879.
   PubMed Web of Science ®Google Scholar
• Azevedo LCP, Toscano CM, Bierrenbach AL. Bacterial meningitis in Brazil: baseline epidemiologic assessment of the decade prior to the introduction of pneumococcal and meningococcal vaccines. PLoS One. 2013;8(6):e64524. doi:10.1371/journal.pone.0064524.
   PubMed Web of Science ®Google Scholar
• Moraes C, de Moraes JC, Silva GDM, Duarte EC. Evaluation of the impact of serogroup C meningococcal disease vaccination program in Brazil and its regions: a population-based study, 2001–2013. Mem Inst Oswaldo Cruz. 2017;112(4):237–46. doi:10.1590/0074-02760160173.
   PubMed Web of Science ®Google Scholar
• Andrade AL, Minamisava R, Tomichet L, Lemos AP, Gorla MC, Brandileone MC, Domingues CMS, de Moraes C, Policena G, Bierrenbach AL, et al. impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil. Vaccine. 2017;35(16):2025–33. doi:10.1080/21645515.2017.1415682.
   PubMed Web of Science ®Google Scholar
• Jeppesen CA, Snape MD, Robinson H, Gossger N, John TM, Voysey M, Ladhani S, Okike IO, Oeser C, Kent A, et al. Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. J Infect. 2015;71(1):43–52. doi:10.1016/j.jinf.2015.02.006.
   PubMed Web of Science ®Google Scholar
• Borrow R, Alarcon P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echániz-Aviles G, Findlow J, Head C, et al. The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2016;16(4):313–28. doi:10.1080/14760584.2017.1258308.
   PubMed Web of Science ®Google Scholar
• McNamara L, Dolan Thomas J, MacNeil J, Chang HY, Day M, Fisher E, Martin S, Poissant T, Schmink S, Steward-Clark E, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak-Oregon, 2015–2016. J Infect Dis. 2017;216:1130–40. doi:10.1093/infdis/jix446.
   PubMed Web of Science ®Google Scholar
• Soeters HM, Whaley M, Alexander-Scott N, Kanadanian KV, Mac-Neil JR, Martin SW, McNamara LA, Sicard K, Vanner C, Vuong J, et al. Meningococcal carriage evaluation in response to a Serogroup B meningococcal disease outbreak and mass vaccination campaign at a College-Rhode Island, 2015–2016. Clin Infect Dis. 2017;64(8):1115–22. doi:10.1093/cid/cix091.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN, et al. Effectiveness and impact of a reduced infant schedule of4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388:2775–82. doi:10.1016/S0140-6736(16)31921-3.
   PubMed Web of Science ®Google Scholar
• Public Health England. Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2018 to 2019. Available from: www.gov.uk/government/publications/meningococcal-disease-laboratory-confirmedcases-in-england-in-2018-to-2019 [accessed Sept 30 2019]
   Google Scholar
• Ladhani S Meningococcal protein vaccines - where next? Abstract number 263125 presented at ESPID in Ljubljana, Slovenia. May 9, 2019.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Interim guidance for control of serogroup B meningococcal disease outbreaks in organizational settings. [accessed 2019 May 30]. https://www.cdc.gov/meningococcal/downloads/interim-guidance.pdf
   Google Scholar
• Medini D, Stella M, Wassil J. MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33:2629–36. doi:10.1016/j.vaccine.2015.04.015.
   PubMed Web of Science ®Google Scholar
• De Moraes JC, Kemp B, de Lemos AP, Gorla MC, Marques EG, Ferreira MD, Sacchi C, Marques Pinto Carvalhanas TR, Ribeiro AF, Ferreira CM, et al. Prevalence, risk factors and molecular characteristics of meningococcal carriage among Brazilian adolescents. Pediatr Infect Dis J. 2015;34:1197–202. doi:10.1371/journal.pone.0166475.
   PubMed Web of Science ®Google Scholar
• Nunes AMPB, Ribeiro GS, Ferreira ÍE, Moura ARSS, Felzemburgh RDM, de Lemos APS, Reis MG, de Moraes JC, Campos LC. Meningococcal carriage among adolescents after mass meningococcal C conjugate vaccination campaigns in Salvador, Brazil. PLoS One. 2016;11(11):e0166475. doi:10.1371/journal.pone.0166475.
   PubMed Web of Science ®Google Scholar